# Business Model Canvas: AI Agentic Playground for Rare Disease Patient-Centric Market Research

## Complete Business Model Canvas (Mermaid Diagram)

```mermaid
graph TB
    subgraph "KEY PARTNERS"
        KP1[Patient Organizations<br/>MGFA, GJCF]
        KP2[Technology Vendors<br/>Cloud, AI/ML Platforms]
        KP3[Market Research Firms<br/>Rare Patient Voice, Thrivable]
        KP4[Academic Institutions<br/>Validation Studies]
        KP5[Regulatory Agencies<br/>FDA, EMA]
    end
    
    subgraph "KEY ACTIVITIES"
        KA1[Agent Development<br/>& Refinement]
        KA2[Knowledge Base<br/>Curation]
        KA3[Simulation Design<br/>& Execution]
        KA4[Validation Studies<br/>with Real Patients]
        KA5[Training & Support<br/>for Users]
        KA6[Continuous Quality<br/>Assurance]
    end
    
    subgraph "KEY RESOURCES"
        KR1[AI/ML Engineering Team<br/>6-8 FTEs]
        KR2[Patient Insights<br/>Specialists]
        KR3[Disease Knowledge<br/>Databases]
        KR4[Patient Registry<br/>Data]
        KR5[Technology<br/>Infrastructure]
        KR6[Patient Organization<br/>Partnerships]
    end
    
    subgraph "VALUE PROPOSITIONS"
        VP1[ğŸ¯ 60-80% Cost Reduction<br/>per Research Cycle]
        VP2[âš¡ 60% Time Savings<br/>4 weeks vs 8-12 weeks]
        VP3[ğŸ“Š 3x Research Scalability<br/>More insights, same resources]
        VP4[ğŸ”¬ Better Trial Design<br/>20% faster enrollment]
        VP5[ğŸ’¡ Deeper Patient Understanding<br/>Multiple perspectives explored]
        VP6[ğŸ¤ Enhanced Patient Engagement<br/>More meaningful interactions]
    end
    
    subgraph "CUSTOMER RELATIONSHIPS"
        CR1[Dedicated Support<br/>Help Desk & Office Hours]
        CR2[Community of Practice<br/>Monthly Sessions]
        CR3[Co-Creation<br/>with Patient Orgs]
        CR4[Training & Certification<br/>3 Levels]
        CR5[Continuous Improvement<br/>User Feedback Integration]
    end
    
    subgraph "CUSTOMER SEGMENTS"
        CS1[PRIMARY: AZ Rare Disease<br/>R&D Teams]
        CS2[Medical Affairs<br/>Patient Engagement]
        CS3[Clinical Development<br/>Protocol Design]
        CS4[Market Access<br/>Value Evidence]
        CS5[Regulatory Affairs<br/>Patient Voice Documentation]
        CS6[EXTERNAL: Patient<br/>Organizations]
    end
    
    subgraph "CHANNELS"
        CH1[Internal Platform<br/>Web-Based Interface]
        CH2[Training Programs<br/>eLearning & Workshops]
        CH3[Community Forums<br/>Slack, SharePoint]
        CH4[Patient Org Portals<br/>Shared Insights]
        CH5[Conferences<br/>DIA, ISPOR]
    end
    
    subgraph "COST STRUCTURE"
        COST1[ğŸ’° Personnel: $1.5M-2M/year<br/>AI Engineers, Patient Insights Specialists]
        COST2[ğŸ’° Technology: $500K-750K/year<br/>Cloud, AI Platforms, Infrastructure]
        COST3[ğŸ’° External Partnerships: $450K-700K/year<br/>Patient Orgs, Market Research, Validation]
        COST4[ğŸ’° Training & Change Mgmt: $100K-150K/year<br/>Curriculum, Materials, Support]
        COST5[ğŸ’° Total Year 1: $2.5M-3.6M | Ongoing: $2M-2.5M/year]
    end
    
    subgraph "REVENUE STREAMS"
        REV1[ğŸ’µ Cost Avoidance: $4.25M-8.2M/year<br/>Across 10 Rare Disease Programs]
        REV2[ğŸ’µ Time Savings Value: $80M<br/>Faster Trial Enrollment]
        REV3[ğŸ’µ Trial Success: $50M-100M<br/>Avoiding Failed Trials]
        REV4[ğŸ’µ Regulatory Success: $100M+<br/>Better Patient Documentation]
        REV5[ğŸ’µ Market Access: $50M-150M<br/>Improved Reimbursement]
        REV6[ğŸ’µ 3-Year ROI: 20-40x<br/>$200M-400M Return]
    end
    
    KP1 -.-> KA4
    KP2 -.-> KR5
    KP3 -.-> KA4
    KP4 -.-> KA4
    KP5 -.-> KA6
    
    KA1 --> VP5
    KA2 --> VP5
    KA3 --> VP2
    KA4 --> VP6
    KA5 --> VP3
    KA6 --> VP4
    
    KR1 --> KA1
    KR2 --> KA2
    KR3 --> KA2
    KR4 --> KA2
    KR5 --> KA3
    KR6 --> KA4
    
    VP1 --> CS1
    VP2 --> CS1
    VP3 --> CS2
    VP4 --> CS3
    VP5 --> CS4
    VP6 --> CS6
    
    CR1 --> CS1
    CR2 --> CS2
    CR3 --> CS6
    CR4 --> CS1
    CR5 --> CS1
    
    CH1 --> CS1
    CH2 --> CS1
    CH3 --> CS2
    CH4 --> CS6
    CH5 --> CS4
    
    CS1 --> REV1
    CS3 --> REV2
    CS3 --> REV3
    CS5 --> REV4
    CS4 --> REV5
    
    KR1 --> COST1
    KR2 --> COST1
    KR5 --> COST2
    KP1 --> COST3
    KP3 --> COST3
    CR4 --> COST4
    
    classDef partners fill:#e1f5ff,stroke:#0066cc,stroke-width:2px
    classDef activities fill:#fff4e1,stroke:#ff9900,stroke-width:2px
    classDef resources fill:#e8f5e9,stroke:#4caf50,stroke-width:2px
    classDef value fill:#f3e5f5,stroke:#9c27b0,stroke-width:3px,font-weight:bold
    classDef customers fill:#fce4ec,stroke:#e91e63,stroke-width:2px
    classDef relationships fill:#e0f2f1,stroke:#009688,stroke-width:2px
    classDef channels fill:#fff9c4,stroke:#f9a825,stroke-width:2px
    classDef costs fill:#ffebee,stroke:#c62828,stroke-width:2px
    classDef revenue fill:#e8f5e9,stroke:#2e7d32,stroke-width:3px,font-weight:bold
    
    class KP1,KP2,KP3,KP4,KP5 partners
    class KA1,KA2,KA3,KA4,KA5,KA6 activities
    class KR1,KR2,KR3,KR4,KR5,KR6 resources
    class VP1,VP2,VP3,VP4,VP5,VP6 value
    class CS1,CS2,CS3,CS4,CS5,CS6 customers
    class CR1,CR2,CR3,CR4,CR5 relationships
    class CH1,CH2,CH3,CH4,CH5 channels
    class COST1,COST2,COST3,COST4,COST5 costs
    class REV1,REV2,REV3,REV4,REV5,REV6 revenue
```

---

## Value Proposition Canvas: Patient Organizations

```mermaid
graph LR
    subgraph "PATIENT GAINS ğŸ"
        PG1[âœ… Amplified Voice<br/>Patient perspectives reach<br/>more decisions]
        PG2[âœ… Faster Research<br/>Accelerated drug<br/>development]
        PG3[âœ… Better Treatments<br/>More patient-centric<br/>therapies]
        PG4[âœ… Reduced Burden<br/>Less over-research<br/>of small community]
        PG5[âœ… Shared Insights<br/>Access to research<br/>findings]
        PG6[âœ… Meaningful Partnership<br/>Co-creation role,<br/>not just consultation]
        PG7[âœ… Community Impact<br/>Influence across<br/>multiple programs]
    end
    
    subgraph "PATIENT PAINS ğŸ˜Ÿ"
        PP1[âŒ Small Patient Populations<br/>Hard to recruit for<br/>every study]
        PP2[âŒ Research Fatigue<br/>Same patients asked<br/>repeatedly]
        PP3[âŒ Limited Influence<br/>Input often comes<br/>too late]
        PP4[âŒ Time Constraints<br/>Volunteer-led orgs<br/>stretched thin]
        PP5[âŒ Geographic Barriers<br/>Patients dispersed<br/>globally]
        PP6[âŒ Slow Development<br/>Years between<br/>input and impact]
        PP7[âŒ Misrepresentation<br/>Concerns about authentic<br/>voice capture]
    end
    
    subgraph "PATIENT JOBS TO BE DONE ğŸ¯"
        PJ1[ğŸ”§ Accelerate Research<br/>for their disease]
        PJ2[ğŸ”§ Ensure Patient Voice<br/>in drug development]
        PJ3[ğŸ”§ Support Community<br/>members effectively]
        PJ4[ğŸ”§ Build Sustainable<br/>partnerships with pharma]
        PJ5[ğŸ”§ Maximize Impact<br/>with limited resources]
    end
    
    subgraph "GAIN CREATORS ğŸ’¡"
        GC1[ğŸ¯ AI Enables Scale<br/>Explore 10x scenarios<br/>without patient burden]
        GC2[ğŸ¯ Early Integration<br/>Patient voice from<br/>day 1 of planning]
        GC3[ğŸ¯ Continuous Input<br/>Ongoing simulation<br/>+ validation cycles]
        GC4[ğŸ¯ Co-Development<br/>Patient orgs review<br/>& approve agents]
        GC5[ğŸ¯ Insight Sharing<br/>Research findings<br/>shared back]
        GC6[ğŸ¯ Multi-Program Impact<br/>One partnership,<br/>many applications]
        GC7[ğŸ¯ Validation Authority<br/>Patient orgs validate<br/>AI accuracy]
    end
    
    subgraph "PAIN RELIEVERS ğŸ’Š"
        PR1[âœ¨ Reduces Over-Research<br/>AI explores options,<br/>patients validate key ones]
        PR2[âœ¨ Overcomes Geography<br/>Virtual engagement<br/>+ AI simulation]
        PR3[âœ¨ Maximizes Efficiency<br/>Focus patient time on<br/>highest-value input]
        PR4[âœ¨ Ensures Authenticity<br/>Rigorous validation<br/>+ patient oversight]
        PR5[âœ¨ Accelerates Impact<br/>Weeks not months<br/>for insights]
        PR6[âœ¨ Sustainable Model<br/>Ongoing partnership<br/>not transactional]
        PR7[âœ¨ Transparent Process<br/>Clear about AI use<br/>+ limitations]
    end
    
    subgraph "PRODUCTS & SERVICES ğŸ› ï¸"
        PS1[ğŸ“¦ AI Agentic Playground<br/>Multi-stakeholder simulation]
        PS2[ğŸ“¦ Validation Framework<br/>Patient-led quality assurance]
        PS3[ğŸ“¦ Co-Development Process<br/>Agent review & approval]
        PS4[ğŸ“¦ Insight Reports<br/>Research findings shared]
        PS5[ğŸ“¦ Partnership Model<br/>Sustainable collaboration]
    end
    
    PJ1 --> GC1
    PJ1 --> GC2
    PJ2 --> GC3
    PJ2 --> GC4
    PJ3 --> GC5
    PJ4 --> GC6
    PJ5 --> GC7
    
    PP1 --> PR1
    PP2 --> PR1
    PP3 --> PR2
    PP4 --> PR3
    PP5 --> PR2
    PP6 --> PR5
    PP7 --> PR4
    
    GC1 --> PG1
    GC2 --> PG6
    GC3 --> PG7
    GC4 --> PG6
    GC5 --> PG5
    GC6 --> PG7
    GC7 --> PG6
    
    PR1 --> PG4
    PR2 --> PG4
    PR3 --> PG4
    PR4 --> PG1
    PR5 --> PG2
    PR6 --> PG6
    PR7 --> PG6
    
    PS1 --> GC1
    PS2 --> PR4
    PS3 --> GC4
    PS4 --> GC5
    PS5 --> PR6
    
    PS1 --> PR1
    PS2 --> GC7
    PS3 --> PR7
    PS4 --> PR5
    PS5 --> GC6
    
    classDef gains fill:#c8e6c9,stroke:#2e7d32,stroke-width:3px,font-weight:bold
    classDef pains fill:#ffcdd2,stroke:#c62828,stroke-width:3px,font-weight:bold
    classDef jobs fill:#fff9c4,stroke:#f57f17,stroke-width:2px
    classDef gainCreators fill:#b2dfdb,stroke:#00695c,stroke-width:2px
    classDef painRelievers fill:#f8bbd0,stroke:#880e4f,stroke-width:2px
    classDef products fill:#e1bee7,stroke:#6a1b9a,stroke-width:2px
    
    class PG1,PG2,PG3,PG4,PG5,PG6,PG7 gains
    class PP1,PP2,PP3,PP4,PP5,PP6,PP7 pains
    class PJ1,PJ2,PJ3,PJ4,PJ5 jobs
    class GC1,GC2,GC3,GC4,GC5,GC6,GC7 gainCreators
    class PR1,PR2,PR3,PR4,PR5,PR6,PR7 painRelievers
    class PS1,PS2,PS3,PS4,PS5 products
```

---

## Value Proposition Canvas: AstraZeneca Internal Teams

```mermaid
graph LR
    subgraph "AZ GAINS ğŸ"
        AG1[âœ… Faster Decisions<br/>60% time reduction<br/>4 weeks vs 8-12]
        AG2[âœ… Cost Savings<br/>60-80% reduction<br/>per research cycle]
        AG3[âœ… Better Trials<br/>20% faster enrollment<br/>15% better retention]
        AG4[âœ… Competitive Edge<br/>Industry-leading<br/>patient-centricity]
        AG5[âœ… Regulatory Success<br/>Stronger patient<br/>documentation]
        AG6[âœ… Market Access<br/>Patient-centric<br/>value evidence]
        AG7[âœ… Scalability<br/>3x more research<br/>same resources]
        AG8[âœ… Risk Mitigation<br/>Test before<br/>real-world implementation]
    end
    
    subgraph "AZ PAINS ğŸ˜Ÿ"
        AP1[âŒ Slow Patient Engagement<br/>8-12 weeks per cycle<br/>delays decisions]
        AP2[âŒ High Costs<br/>$525K-1M annually<br/>per program]
        AP3[âŒ Limited Scalability<br/>Can't engage patients<br/>for every question]
        AP4[âŒ Trial Enrollment Challenges<br/>18-24 months to enroll<br/>retention issues]
        AP5[âŒ Protocol Amendments<br/>Expensive changes<br/>after patient feedback]
        AP6[âŒ Geographic Constraints<br/>Patients dispersed<br/>hard to convene]
        AP7[âŒ Competing Priorities<br/>Multiple stakeholders<br/>conflicting needs]
        AP8[âŒ Regulatory Pressure<br/>FDA/EMA demand<br/>patient voice evidence]
    end
    
    subgraph "AZ JOBS TO BE DONE ğŸ¯"
        AJ1[ğŸ”§ Design Patient-Centric<br/>Clinical Trials]
        AJ2[ğŸ”§ Optimize Patient<br/>Support Programs]
        AJ3[ğŸ”§ Build Regulatory<br/>Submissions]
        AJ4[ğŸ”§ Develop Market<br/>Access Strategy]
        AJ5[ğŸ”§ Navigate Ethical<br/>Dilemmas]
        AJ6[ğŸ”§ Accelerate Drug<br/>Development]
    end
    
    subgraph "GAIN CREATORS ğŸ’¡"
        AGC1[ğŸ¯ Rapid Simulation<br/>Explore scenarios<br/>in days not months]
        AGC2[ğŸ¯ Multi-Perspective Analysis<br/>Patient, advocate, org,<br/>AZ views simultaneously]
        AGC3[ğŸ¯ Scenario Planning<br/>Test multiple options<br/>before commitment]
        AGC4[ğŸ¯ Early Problem Detection<br/>Identify issues before<br/>expensive amendments]
        AGC5[ğŸ¯ Evidence Generation<br/>Patient preference data<br/>for submissions]
        AGC6[ğŸ¯ Validated Insights<br/>AI + real patient<br/>validation]
        AGC7[ğŸ¯ Continuous Learning<br/>Agents improve<br/>with each use]
        AGC8[ğŸ¯ Cross-Program Leverage<br/>Learnings apply<br/>across portfolio]
    end
    
    subgraph "PAIN RELIEVERS ğŸ’Š"
        APR1[âœ¨ 60% Time Reduction<br/>4 weeks vs 8-12 weeks<br/>per research cycle]
        APR2[âœ¨ 60-80% Cost Reduction<br/>$100K-180K vs<br/>$525K-1M per program]
        APR3[âœ¨ 3x Scalability<br/>More research with<br/>same resources]
        APR4[âœ¨ Better Protocol Design<br/>Upfront optimization<br/>reduces amendments]
        APR5[âœ¨ Improved Enrollment<br/>Patient-centric design<br/>attracts participants]
        APR6[âœ¨ Virtual Engagement<br/>Overcome geographic<br/>barriers]
        APR7[âœ¨ Stakeholder Alignment<br/>Surface tensions<br/>early, find solutions]
        APR8[âœ¨ Regulatory Confidence<br/>Comprehensive patient<br/>voice documentation]
    end
    
    subgraph "PRODUCTS & SERVICES ğŸ› ï¸"
        APS1[ğŸ“¦ AI Agentic Playground<br/>Multi-stakeholder simulation]
        APS2[ğŸ“¦ Use Case Templates<br/>Protocol optimization,<br/>support programs, etc.]
        APS3[ğŸ“¦ Training & Certification<br/>3-level curriculum]
        APS4[ğŸ“¦ Validation Framework<br/>Real patient comparison]
        APS5[ğŸ“¦ Insight Reports<br/>Actionable recommendations]
        APS6[ğŸ“¦ Community of Practice<br/>Best practice sharing]
    end
    
    AJ1 --> AGC1
    AJ1 --> AGC3
    AJ2 --> AGC2
    AJ3 --> AGC5
    AJ4 --> AGC5
    AJ5 --> AGC2
    AJ6 --> AGC1
    
    AP1 --> APR1
    AP2 --> APR2
    AP3 --> APR3
    AP4 --> APR5
    AP5 --> APR4
    AP6 --> APR6
    AP7 --> APR7
    AP8 --> APR8
    
    AGC1 --> AG1
    AGC2 --> AG8
    AGC3 --> AG8
    AGC4 --> AG3
    AGC5 --> AG5
    AGC6 --> AG4
    AGC7 --> AG7
    AGC8 --> AG7
    
    APR1 --> AG1
    APR2 --> AG2
    APR3 --> AG7
    APR4 --> AG3
    APR5 --> AG3
    APR6 --> AG7
    APR7 --> AG8
    APR8 --> AG5
    
    APS1 --> AGC1
    APS2 --> AGC3
    APS3 --> APR3
    APS4 --> AGC6
    APS5 --> AGC4
    APS6 --> AGC8
    
    APS1 --> APR1
    APS2 --> APR4
    APS3 --> APR3
    APS4 --> APR8
    APS5 --> APR7
    APS6 --> APR3
    
    classDef gains fill:#c8e6c9,stroke:#2e7d32,stroke-width:3px,font-weight:bold
    classDef pains fill:#ffcdd2,stroke:#c62828,stroke-width:3px,font-weight:bold
    classDef jobs fill:#fff9c4,stroke:#f57f17,stroke-width:2px
    classDef gainCreators fill:#b2dfdb,stroke:#00695c,stroke-width:2px
    classDef painRelievers fill:#f8bbd0,stroke:#880e4f,stroke-width:2px
    classDef products fill:#e1bee7,stroke:#6a1b9a,stroke-width:2px
    
    class AG1,AG2,AG3,AG4,AG5,AG6,AG7,AG8 gains
    class AP1,AP2,AP3,AP4,AP5,AP6,AP7,AP8 pains
    class AJ1,AJ2,AJ3,AJ4,AJ5,AJ6 jobs
    class AGC1,AGC2,AGC3,AGC4,AGC5,AGC6,AGC7,AGC8 gainCreators
    class APR1,APR2,APR3,APR4,APR5,APR6,APR7,APR8 painRelievers
    class APS1,APS2,APS3,APS4,APS5,APS6 products
```

---

## Detailed Gains & Pain Relievers Summary

### For Patient Organizations

```mermaid
mindmap
  root((Patient Organizations<br/>Value))
    MAIN GAINS
      Amplified Voice
        Patient perspectives reach more decisions
        Influence across multiple programs
        Early integration in planning
      Reduced Burden
        Less over-research of small community
        Focus on highest-value input
        Sustainable partnership model
      Faster Impact
        Weeks not months for insights
        Accelerated drug development
        Better treatments sooner
      Meaningful Partnership
        Co-creation role not just consultation
        Validation authority
        Shared insights and benefits
    MAIN PAIN RELIEVERS
      Overcomes Small Populations
        AI explores 10x scenarios
        Patients validate key decisions only
        Maximizes limited community
      Reduces Research Fatigue
        Same patients not asked repeatedly
        Strategic use of patient time
        Virtual engagement options
      Ensures Authenticity
        Rigorous validation framework
        Patient org reviews agents
        Transparent about AI use
      Accelerates Development
        60% time savings per cycle
        Earlier patient voice integration
        Faster path to approval
```

---

### For AstraZeneca

```mermaid
mindmap
  root((AstraZeneca<br/>Value))
    MAIN GAINS
      Efficiency
        60% time reduction
        60-80% cost savings
        3x research scalability
      Trial Success
        20% faster enrollment
        15% better retention
        Fewer protocol amendments
      Competitive Advantage
        Industry-leading patient-centricity
        Regulatory confidence
        Market access success
      Risk Mitigation
        Test before implementation
        Early problem detection
        Validated insights
    MAIN PAIN RELIEVERS
      Speed
        4 weeks vs 8-12 weeks
        Rapid scenario exploration
        Parallel option testing
      Cost
        $100K-180K vs $525K-1M
        Avoid expensive amendments
        Maximize resource efficiency
      Quality
        Better protocol design upfront
        Comprehensive patient perspective
        Multi-stakeholder alignment
      Scale
        More programs covered
        Continuous patient voice
        Cross-portfolio learning
```

---

## ROI & Impact Visualization

```mermaid
graph TD
    subgraph "INVESTMENT"
        I1[Year 1: $2.5M-3.6M]
        I2[Ongoing: $2M-2.5M/year]
        I3[Total 3-Year: $8M-10M]
    end
    
    subgraph "COST AVOIDANCE"
        CA1[Traditional Research: $525K-1M/program/year]
        CA2[AI Approach: $100K-180K/program/year]
        CA3[Savings: $425K-820K/program/year]
        CA4[Across 10 Programs: $4.25M-8.2M/year]
    end
    
    subgraph "TIME VALUE"
        TV1[Trial Enrollment: 2 months faster]
        TV2[Cost of Delay: $8M/month]
        TV3[Value per Trial: $16M]
        TV4[Across 5 Trials: $80M]
    end
    
    subgraph "TRIAL SUCCESS"
        TS1[Better Protocol Design]
        TS2[Improved Retention: 15%]
        TS3[Avoid 1 Failed Trial]
        TS4[Value: $50M-100M]
    end
    
    subgraph "REGULATORY & MARKET ACCESS"
        RM1[Stronger Patient Documentation]
        RM2[Better Reimbursement Outcomes]
        RM3[Favorable Labeling]
        RM4[Value: $150M-250M]
    end
    
    subgraph "TOTAL ROI"
        ROI1[3-Year Return: $200M-400M]
        ROI2[ROI Multiple: 20-40x]
        ROI3[Payback Period: 6-9 months]
    end
    
    I1 --> I3
    I2 --> I3
    
    CA1 --> CA3
    CA2 --> CA3
    CA3 --> CA4
    
    TV1 --> TV3
    TV2 --> TV3
    TV3 --> TV4
    
    TS1 --> TS2
    TS2 --> TS3
    TS3 --> TS4
    
    RM1 --> RM2
    RM2 --> RM3
    RM3 --> RM4
    
    I3 -.->|Investment| ROI1
    CA4 -.->|Savings| ROI1
    TV4 -.->|Time Value| ROI1
    TS4 -.->|Trial Success| ROI1
    RM4 -.->|Market Value| ROI1
    
    ROI1 --> ROI2
    ROI1 --> ROI3
    
    classDef investment fill:#ffcdd2,stroke:#c62828,stroke-width:2px
    classDef savings fill:#c8e6c9,stroke:#2e7d32,stroke-width:2px
    classDef value fill:#b2dfdb,stroke:#00695c,stroke-width:2px
    classDef roi fill:#fff9c4,stroke:#f57f17,stroke-width:3px,font-weight:bold
    
    class I1,I2,I3 investment
    class CA1,CA2,CA3,CA4 savings
    class TV1,TV2,TV3,TV4,TS1,TS2,TS3,TS4,RM1,RM2,RM3,RM4 value
    class ROI1,ROI2,ROI3 roi
```

---

## Key Metrics Dashboard

```mermaid
graph TB
    subgraph "EFFICIENCY METRICS"
        EM1[â±ï¸ Time-to-Insight<br/>Target: 4 weeks<br/>Baseline: 8-12 weeks<br/>Improvement: 60%]
        EM2[ğŸ’° Cost-per-Insight<br/>Target: $100K-180K<br/>Baseline: $525K-1M<br/>Savings: 60-80%]
        EM3[ğŸ“Š Research Scalability<br/>Target: 8-10 activities/program/year<br/>Baseline: 2-3 activities/program/year<br/>Increase: 3x]
    end
    
    subgraph "QUALITY METRICS"
        QM1[âœ… Agent Realism<br/>Target: 80%+ "realistic"<br/>Measured: Expert review]
        QM2[âœ… Validation Alignment<br/>Target: 85%+ match<br/>Measured: Patient comparison]
        QM3[âœ… Actionable Insights<br/>Target: 70%+ implemented<br/>Measured: Decision tracking]
    end
    
    subgraph "BUSINESS IMPACT"
        BI1[ğŸ¯ Trial Enrollment<br/>Target: 20% faster<br/>Measured: Enrollment timelines]
        BI2[ğŸ¯ Trial Retention<br/>Target: 15% improvement<br/>Measured: Completion rates]
        BI3[ğŸ¯ Regulatory Success<br/>Target: 90%+ with patient evidence<br/>Measured: Submission quality]
        BI4[ğŸ¯ Market Access<br/>Target: 10-15% better outcomes<br/>Measured: Coverage decisions]
    end
    
    subgraph "STAKEHOLDER SATISFACTION"
        SS1[ğŸ˜Š AZ User Satisfaction<br/>Target: 80%+ "valuable"<br/>Measured: Post-use surveys]
        SS2[ğŸ˜Š Patient Org Satisfaction<br/>Target: 80%+ "excellent"<br/>Measured: Partnership reviews]
        SS3[ğŸ˜Š Patient Community Sentiment<br/>Target: Positive perception<br/>Measured: Sentiment analysis]
    end
    
    EM1 --> Success[ğŸ† SUCCESS<br/>CRITERIA<br/>MET]
    EM2 --> Success
    EM3 --> Success
    QM1 --> Success
    QM2 --> Success
    QM3 --> Success
    BI1 --> Success
    BI2 --> Success
    BI3 --> Success
    BI4 --> Success
    SS1 --> Success
    SS2 --> Success
    SS3 --> Success
    
    classDef efficiency fill:#e3f2fd,stroke:#1976d2,stroke-width:2px
    classDef quality fill:#f3e5f5,stroke:#7b1fa2,stroke-width:2px
    classDef business fill:#e8f5e9,stroke:#388e3c,stroke-width:2px
    classDef satisfaction fill:#fff3e0,stroke:#f57c00,stroke-width:2px
    classDef success fill:#c8e6c9,stroke:#2e7d32,stroke-width:4px,font-weight:bold
    
    class EM1,EM2,EM3 efficiency
    class QM1,QM2,QM3 quality
    class BI1,BI2,BI3,BI4 business
    class SS1,SS2,SS3 satisfaction
    class Success success
```

---

## Summary: Top Gains & Pain Relievers

### ğŸ **TOP 5 GAINS FOR PATIENTS**

1. **Amplified Voice** - Patient perspectives influence more decisions across more programs
2. **Reduced Burden** - Less over-research of small communities; focus on highest-value input
3. **Faster Treatments** - Accelerated development means better therapies reach patients sooner
4. **Meaningful Partnership** - Co-creation role with validation authority, not just consultation
5. **Community Impact** - One partnership creates influence across entire rare disease portfolio

### ğŸ’Š **TOP 5 PAIN RELIEVERS FOR PATIENTS**

1. **Overcomes Small Populations** - AI explores 10x scenarios; patients validate only key decisions
2. **Reduces Research Fatigue** - Same patients not asked repeatedly for every question
3. **Ensures Authenticity** - Rigorous validation + patient organization oversight guarantees accurate representation
4. **Accelerates Impact** - 60% time savings means faster path from input to implementation
5. **Sustainable Model** - Ongoing partnership with shared benefits, not transactional engagement

---

### ğŸ **TOP 5 GAINS FOR ASTRAZENECA**

1. **Dramatic Efficiency** - 60% time savings + 60-80% cost reduction per research cycle
2. **Better Trial Performance** - 20% faster enrollment, 15% better retention through patient-centric design
3. **Competitive Advantage** - Industry-leading patient-centricity with measurable outcomes
4. **Regulatory Confidence** - Comprehensive patient voice documentation strengthens submissions
5. **Scalability** - 3x more research with same resources across entire rare disease portfolio

### ğŸ’Š **TOP 5 PAIN RELIEVERS FOR ASTRAZENECA**

1. **Speed to Insight** - 4 weeks vs 8-12 weeks; rapid scenario exploration enables faster decisions
2. **Cost Efficiency** - $100K-180K vs $525K-1M per program annually; $4.25M-8.2M savings across 10 programs
3. **Protocol Optimization** - Upfront patient input reduces expensive protocol amendments
4. **Risk Mitigation** - Test multiple options before real-world implementation; early problem detection
5. **Geographic Freedom** - Virtual engagement + AI simulation overcome patient dispersion challenges

---

### ğŸ’° **FINANCIAL SUMMARY**

**Investment**: $8M-10M over 3 years  
**Return**: $200M-400M  
**ROI Multiple**: 20-40x  
**Payback Period**: 6-9 months

**Value Drivers**:
- Cost avoidance: $4.25M-8.2M/year
- Time value: $80M (faster enrollment)
- Trial success: $50M-100M (avoiding failures)
- Regulatory/market access: $150M-250M (better outcomes)

---

This business model canvas demonstrates that the AI Agentic Playground creates **mutual value** for both patients and AstraZenecaâ€”amplifying patient voices while dramatically improving efficiency, quality, and outcomes for rare disease drug development.